HSBC raises target for Merck & Co. stock to USD 175.00

Published on 10/27/2026 at 17:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck reports third-quarter results October 29, 2026. Merck & Co. stock costs EUR 127.87 on October 27, 2026, up 0.20 percent versus Xetra's close.

Analyst target and earnings date

HSBC lifted its Merck target from USD 172.00 to USD 175.00 on October 19, 2026.
The target stands 22.97 percent above Merck's USD 142.34 NYSE price on October 27, 2026.
Merck & Co. stock costs EUR 127.87 at Lang & Schwarz on October 27, 2026 at 5:07 p.m. CEST, 0.20 percent above the Xetra close of October 27, 2026.
Merck is scheduled to report third-quarter results on October 29, 2026.

Merck & Co., US58933Y1055, Illustration mit AI erstellt.

On October 19, 2026, HSBC raised its price target for Merck & Co. from USD 172.00 to USD 175.00, according to MarketScreener. Merck & Co. stock was trading at EUR 127.87 at Lang & Schwarz on October 27, 2026 at 5:07 p.m. CEST, up 0.20 percent versus the Xetra close of October 27, 2026 at EUR 127.62.

HSBC target leaves room for upside

Merck's NYSE price was USD 142.34 on October 27, 2026 at 12:12 p.m. EDT. The HSBC target therefore stood 22.97 percent above that price, using the same USD currency for the comparison.

The target change came as the next reporting date approached. Merck's investor-relations calendar lists its ESMO investor event on October 26, 2026, while the latest market calendar identified October 29, 2026 as the date for the third-quarter report.

Merck stock remains below its yearly high

Merck's USD 82.01 to USD 156.92 52-week range puts the October 27 price USD 14.58 below the high, a 9.29 percent gap. The company had a market capitalization of USD 351.2 billion and a price-to-earnings ratio of 113.93 at the same market snapshot.

Trading volume was 2,828,841 shares at 12:12 p.m. EDT. The price position matters because the HSBC target is above the current quotation, while the stock remains below its yearly peak rather than setting a new high.

How does Merck compare?

Comparison with peers

Merck & Co.: 0.20 percent above the Xetra close, price-to-earnings ratio 113.93, market capitalization USD 351.2 billion.

Bristol-Myers Squibb Company (NYSE, USD): down 0.38 percent, price-to-earnings ratio 13.53, market capitalization USD 125.4 billion.

Johnson & Johnson (NYSE, USD): up 0.50 percent, price-to-earnings ratio 40.60, market capitalization USD 644.3 billion.

October 29 is the next date

Merck's next scheduled corporate date is its third-quarter results release on October 29, 2026, before the US market opens, as reported by TipRanks. The upcoming report gives investors a near-term checkpoint for revenue, earnings and the pipeline.

Price holds just above the Xetra close

Merck & Co. stock was trading at EUR 127.87 at Lang & Schwarz on October 27, 2026 at 5:07 p.m. CEST, 0.20 percent above the Xetra close of October 27, 2026 at EUR 127.62. The USD 175.00 HSBC target and the October 29 reporting date are the next dated reference points for the stock.

The further course of trading is shown by the continuously updated real-time quote of Merck & Co stock.